Lumida
/MGPI
⌘K
MGP Ingredients Inc

MGP Ingredients Inc

MGPI
$17.86USD-2.78%-0.51 today

MARKET CAP

381.7M

P/E (TTM)

6.9x

FWD P/E

9.2x

DAY RANGE

$18 – $19

52W RANGE

$16
$33

AI Summary

Stalk
StalkMedium

MGPI is trading in a Stage 4 decline with a long-term downtrend, but oversold conditions and mean-reversion eligibility near historical valuation lows allow for a tactical buy-side stance. Medium-term bias is Bullish for mean-reversion only, while short-term execution readiness is Neutral as price pulls into declining EMAs without decisive follow-through. Key resistance lies at the 9/21 EMAs and 50 SMA, and failure to reclaim these or a breakdown below recent support would invalidate this bias.

  • Penelope Bourbon brand drove 10% YoY sales growth in Premium Plus
  • Cash flow from operations rose 82% YoY to $44.7M in Q1’26
  • Q1’26 revenue fell 13% YoY to $106.4M on broad segment declines
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

MGP Ingredients, Inc. (NASDAQ: MGPI) is a leading player in the spirits and specialty food ingredient industries. They are particularly famous for producing premium distilled spirits, including whiskey and artisan ingredients that cater to the evolving demands of both the retail and food service sectors. The company is well-positioned in the premiumization trend within the beverage industry, focusing on enhancing brand quality and operational efficiency amidst rising competition and market volatility.

Bull says

  • Penelope Bourbon brand drove 10% YoY sales growth in Premium Plus
  • Cash flow from operations rose 82% YoY to $44.7M in Q1’26
  • A&P spend up >200% and Breakthrough partnership expands premium reach
  • Operational efficiency improved 14%; CapEx cut 75% to $2M supports margins
  • Strong earnings yield and book-to-price ratio, solid liquidity, low leverage
  • Dividend yield ~0.7% provides modest income cushion

Bear says

  • Q1’26 revenue fell 13% YoY to $106.4M on broad segment declines
  • Adjusted EBITDA dropped 31% YoY to $15M; gross margin slid 400bp to 31.6%
  • Reported $134.8M net loss driven by goodwill impairment charge
  • Negative growth and profitability factors indicate deeper operational headwinds
  • Shares dipped ~2.6% post-earnings; low institutional interest signals weak demand
  • Intense competition and economic pressure threaten market share

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-30-2026neutral

Transcript signals

Bull points

  • Sales in the first quarter of 2026 came in at $106.4 million, down versus the prior year, but in line with our expectations. Adjusted EBITDA of $15 million and adjusted basic EPS of 15 cents also declined versus the first quarter of last year. However, both of these key metrics were ahead of expectations. We are pleased with this performance as it helps to validate the work we've been doing to drive progress in our business while simultaneously navigating a challenging industry backdrop.
  • While this temporary idling will unfortunately affect 33 employees, it is not expected to impact the availability of our products or our services to our customers, and it is necessary to adjust our production to align with current inventory levels.
  • Importantly, gross margin expanded 180 basis points to 47.8%, reflecting improved mix and early benefits from our revenue growth management initiatives.

Bear points

  • despite a year-over-year decline for the first quarter, we are seeing early signs of stabilization and recovery, supported by deliberate investments in innovation and digital capabilities.
  • we have initiated comprehensive portfolio review and rationalization. During the first quarter of 2026, we discontinued more than 30 tail brands with approximately 15 additional brands planned to be discontinued by the end of this year.
  • despite the challenging domestic whiskey supply environment, our first quarter results came in as expected. Segment sales of $28 million decreased 40% over a year, while gross profit of $8.6 million declined 54% as elevated inventory levels continued.
Read full transcript analysis ›